Arpida AG Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Reinach Switzerland (1997)
Status: Acquired by Evolva SA (2009)

Organization Overview

First Clinical Trial
2005
NCT00299520
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

iclaprim mesylate (3 trials)

linezolid (zyvox) (2 trials)

Drugs in Phase 2 Trials (2)

Key: Arpida AG (1) Acquired (1)

pf-114 (1 trial)

vancomycin (Vancocin) (1 trial)

Drugs in Phase 1 Trials (2)

Key: Arpida AG (0) Acquired (2)

[111in]-fpi-1547 (1 trial)

[225ac]-fpi-1434 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Healthcare-Associated Pneumonia (Phase 2)

Infections (Phase 3)

Pneumonia (Phase 2)

Pneumonia, Ventilator-Associated (Phase 2)

Skin Diseases (Phase 3)

Skin Diseases, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 6